Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Daily News

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

Yael L. Maxwell

October 24, 2022

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Caitlin E. Cox

August 31, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

Todd Neale

July 20, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Yael L. Maxwell

March 01, 2022

News Daily News

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Michael O'Riordan

February 14, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

Advertisement

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Too Few Veterans Get Intensified Lipid-Lowering Therapy After Coronary Events

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis

Absence of CAC May be Protective Even in Patients With Very High Cholesterol

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content